From genome sequencing to the discovery of potential biomarkers in liver disease

BMB Rep. 2020 Jun;53(6):299-310. doi: 10.5483/BMBRep.2020.53.6.074.


Chronic liver disease progresses through several stages, fatty liver, steatohepatitis, cirrhosis, and eventually, it leads to hepatocellular carcinoma (HCC) over a long period of time. Since a large proportion of patients with HCC are accompanied by cirrhosis, it is considered to be an important factor in the diagnosis of liver cancer. This is because cirrhosis leads to an irreversible harmful effect, but the early stages of chronic liver disease could be reversed to a healthy state. Therefore, the discovery of biomarkers that could identify the early stages of chronic liver disease is important to prevent serious liver damage. Biomarker discovery at liver cancer and cirrhosis has enhanced the development of sequencing technology. Next generation sequencing (NGS) is one of the representative technical innovations in the biological field in the recent decades and it is the most important thing to design for research on what type of sequencing methods are suitable and how to handle the analysis steps for data integration. In this review, we comprehensively summarized NGS techniques for identifying genome, transcriptome, DNA methylome and 3D/4D chromatin structure, and introduced framework of processing data set and integrating multi-omics data for uncovering biomarkers. [BMB Reports 2020; 53(6): 299-310].

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / genetics*
  • Carcinoma, Hepatocellular / diagnosis
  • Carcinoma, Hepatocellular / genetics*
  • High-Throughput Nucleotide Sequencing*
  • Humans
  • Liver Cirrhosis / diagnosis
  • Liver Cirrhosis / genetics*
  • Liver Neoplasms / diagnosis
  • Liver Neoplasms / genetics*


  • Biomarkers, Tumor